New drugs and indications in 2014. Some advances this year, but many drugs are poorly evaluated, too expensive, or more dangerous than useful
Prescrire International 24(159): 107-110
2015
ISSN/ISBN: 1167-7422 PMID: 25941710 Document Number: 684728
Three drugs analysed by Prescrire in 2014 provided a significant therapeutic advance for some patients. In 2014, too many drugs are still best avoided, have undergone minimal evaluation, or are excessively expensive. Drug regulatory agencies should continue their efforts to improve pharmacovigilance and transparency.